Combination of ultrasound and serological tests for detecting occult lateral lymph node metastases in medullary thyroid cancer

To investigate the value of ultrasound and serum marker tests in detecting lateral lymph node metastasis in medullary thyroid cancer (MTC).

[1]  Fan Wu,et al.  The Prediction of Metastases of Lateral Cervical Lymph Node in Medullary Thyroid Carcinoma , 2021, Frontiers in Endocrinology.

[2]  Xianghui He,et al.  Medullary Thyroid Carcinoma With Elevated Serum CEA and Normal Serum Calcitonin After Surgery: A Case Report and Literature Review , 2020, Frontiers in Oncology.

[3]  Jee Soo Kim,et al.  Preoperative Serum Calcitonin and Its Correlation with Extent of Lymph Node Metastasis in Medullary Thyroid Carcinoma , 2020, Cancers.

[4]  Wei Liu,et al.  Risk Factors for Lateral Lymph Node Metastases in Patients With Sporadic Medullary Thyroid Carcinoma , 2020, Technology in cancer research & treatment.

[5]  Yang Yu,et al.  Thyroid cancer neck lymph nodes metastasis: Meta-analysis of US and CT diagnosis. , 2020, European journal of radiology.

[6]  Wenyue Sun,et al.  HIGH RATIO OF EARLY POSTOPERATIVE CALCITONIN TO PREOPERATIVE CALCITONIN COULD BE A NOVEL INDICATOR OF POOR PROGNOSIS IN PATIENTS WITH BIOCHEMICAL INCOMPLETE RESPONSES IN SPORADIC MEDULLARY THYROID CANCER. , 2020, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.

[7]  Soon-Hyun Ahn,et al.  Significance of neck dissection for the treatment of clinically-evident medullary thyroid carcinomas: A systematic review. , 2019, Auris, nasus, larynx.

[8]  T. Aas,et al.  The Role of Calcitonin in Predicting the Extent of Surgery in Medullary Thyroid Carcinoma: A Nationwide Population-Based Study in Norway , 2019, European Thyroid Journal.

[9]  I. Ganly,et al.  Serum calcitonin nadirs to undetectable levels within 1 month of curative surgery in medullary thyroid cancer. , 2019, Archives of endocrinology and metabolism.

[10]  Steven,et al.  Revised American Thyroid Association Guidelines for the Management of Medullary Thyroid Carcinoma , 2018, Pediatrics.

[11]  G. Karanikas,et al.  Medullary Thyroid Carcinoma: Do Ultrasonography and F-DOPA-PET-CT Influence the Initial Surgical Strategy? , 2018, Annals of Surgical Oncology.

[12]  A. Miyauchi,et al.  Static Prognostic Factors and Appropriate Surgical Designs for Patients with Medullary Thyroid Carcinoma: The Second Report from a Single-Institution Study in Japan , 2018, World Journal of Surgery.

[13]  C. Xiao,et al.  Analysis of risk factors for cervical lymph node metastases in patients with sporadic medullary thyroid carcinoma , 2018, The Journal of international medical research.

[14]  Jeong Hyun Lee,et al.  Preoperative Clinical and Sonographic Predictors for Lateral Cervical Lymph Node Metastases in Sporadic Medullary Thyroid Carcinoma. , 2018, Thyroid : official journal of the American Thyroid Association.

[15]  P. Perros,et al.  Management of thyroid cancer: United Kingdom National Multidisciplinary Guidelines , 2016, The Journal of Laryngology & Otology.

[16]  S. Morrone,et al.  Preclinical testing of selective Aurora kinase inhibitors on a medullary thyroid carcinoma-derived cell line , 2016, Endocrine.

[17]  C. Haglund,et al.  Lymph node metastases and elevated postoperative calcitonin: Predictors of poor survival in medullary thyroid carcinoma , 2016, Acta oncologica.

[18]  R. Kurzrock,et al.  Aurora Kinase Inhibitors in Oncology Clinical Trials: Current State of the Progress. , 2015, Seminars in oncology.

[19]  S. Barollo,et al.  Selective inhibitors of aurora kinases inhibit proliferation, reduce cell viability and impair cell cycle progression in papillary thyroid carcinoma cells. , 2015, Journal of biological regulators and homeostatic agents.

[20]  Douglas B. Evans,et al.  Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma. , 2015, Thyroid : official journal of the American Thyroid Association.

[21]  A. Antonelli,et al.  Effects of selective inhibitors of Aurora kinases on anaplastic thyroid carcinoma cell lines. , 2014, Endocrine-related cancer.

[22]  A. Antonelli,et al.  The dual Aurora kinase inhibitor ZM447439 prevents anaplastic thyroid cancer cell growth and tumorigenicity. , 2013, Journal of biological regulators and homeostatic agents.

[23]  A. Pinchera,et al.  Advances in the follow-up of differentiated or medullary thyroid cancer , 2012, Nature Reviews Endocrinology.

[24]  M. Pelizzo,et al.  Aurora kinases are expressed in medullary thyroid carcinoma (MTC) and their inhibition suppresses in vitro growth and tumorigenicity of the MTC derived cell line TT , 2011, BMC Cancer.

[25]  Xavier Robin,et al.  pROC: an open-source package for R and S+ to analyze and compare ROC curves , 2011, BMC Bioinformatics.

[26]  H. Dralle,et al.  Biomarker-based risk stratification for previously untreated medullary thyroid cancer. , 2010, The Journal of clinical endocrinology and metabolism.

[27]  M. Saif,et al.  Aurora kinase inhibitors as anti-cancer therapy , 2010, Anti-cancer drugs.

[28]  P. Schneider,et al.  Prognostic Value of Lymph Node Yield and Metastatic Lymph Node Ratio in Medullary Thyroid Carcinoma , 2008, Annals of Surgical Oncology.

[29]  S. Ismailov,et al.  Postoperative calcitonin study in medullary thyroid carcinoma. , 2004, Endocrine-related cancer.

[30]  R Core Team,et al.  R: A language and environment for statistical computing. , 2014 .

[31]  R. Hinze,et al.  Pattern of Nodal Metastasis for Primary and Reoperative Thyroid Cancer , 2001, World Journal of Surgery.